Logo Image
|Articles|April 1, 2021

Jones Lang LaSalle Releases Emerging Life Sciences Markets Index

Next tier of markets is poised to ascend and offer valuable opportunities to both investors and occupiers.

JLL, a global commercial real estate services company, has released its Emerging Life Sciences Markets Index. The report evaluates metro areas with respect to a wide variety of metrics chosen to best reflect the most critical qualities of life sciences markets on the upswing.

Examining 110 US markets, the index highlights where life sciences jobs are growing the most as well as what markets are accelerating and keeping a full pipeline of talent. The result of this research is a three-pronged model:

  • Momentum: measures the size of the life sciences employment base and the industry’s momentum
  • Talent: measures educational attainment and demographic tailwinds
  • Potential: measures forecasted growth of key market performance indicators such as millennial population, median household income growth, and housing availability

For more information and the full report, click here.

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Addressing MFN Innovation Concerns
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Read more